 |
selumetinib |
|---|---|
| Trade Name | |
| Orphan Indication | Adjuvant treatment of patients with stage III or stage IV differentiated thyroid cancer |
| USA Market Approval | USA |
| USA Designation Date | 2016-05-10 00:00:00 |
| Sponsor | AstraZeneca Pharmaceuticals LP;1800 Concord Pike, P. O. Box 8355;Wilmington, Delaware, 19803 |
